CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 143 enrolled
Drug / intervention
Abstral Oral Disintegrating Tablet (ODT)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03895762
NCT03895762N/ACompleted
CompareCT.gov

An Observational Study to Assess the Efficacy, Safety, and Tolerability of Abstral Oral Disintegrating Tablet (ODT) for the Management of Breakthrough Cancer Pain in Korean Cancer Patients

A.Menarini Asia-Pacific Holdings Pte Ltd·observational·Posted Mar 29, 2019·Updated May 5, 2022

In Brief

An observational study evaluating Abstral Oral Disintegrating Tablet (ODT) for Breakthrough Cancer Pain. Completed, enrolled 143 participants across 1 site.

Detailed Summary

The purpose of this observational study is: To observe the efficacy, safety, and tolerability of Abstral ODT for the alleviation of breakthrough cancer pain in Korean patients with various cancers in real-world clinical settings and supplement and expand the previous cross-sectional survey results.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreakthrough Cancer Pain
CountriesSouth Korea
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedMar 29, 2019
Enrollment StartJul 4, 2017
Primary CompletionJun 28, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7.3 years ago

Interventions

Abstral Oral Disintegrating Tablet (ODT)drug

Opioid(Fentanyl)